Volumina Medical SA: Company Market Research Report
Company Overview
- Name: Volumina Medical SA
- Mission: Volumina Medical aims to develop highly innovative biomaterials for regenerative medicine, addressing unmet needs in reconstructive and plastic surgery markets.
- Founded: No information is available.
- Founders:
- Amélie Béduer, PhD – Founder and CEO, Board Member
- Prof. Thomas Braschler – Founder and CSO
- Prof. Philippe Renaud – Founder
- Key People:
- Amélie Béduer, PhD – CEO, Board Member
- Prof. Stefan Catsicas – Board Member
- Beat Schillig – Board Member
- Emmanuel de Watteville – Board Member
- Silvia Scherer – Chairwoman of the Board of Directors
- Headquarters: Biopôle - Alanine, Route de la Corniche 5, 1066 Epalinges, Switzerland
- Number of Employees: No information is available.
- Revenue: No information is available.
- Known For: Developing a platform of novel injectable biomaterials such as AdiPearl™ for regenerative medicine, particularly for reconstructive and plastic surgery.
Products
- AdiPearl™:
- Description: A biomaterial injection-based solution for reconstructing soft tissue, minimally invasive, and designed to facilitate tissue regeneration.
- Key Features:
- Minimally invasive injection procedure.
- Soft and structuring material, similar to natural tissue.
- Swiss innovation, emerging from extensive research at the Swiss Federal Institute of Technology Lausanne (EPFL).
- Recognized technology with high market potential.
- Technological Benefit: Offers potential alternatives to current treatments such as tissue ablation and aging.
Recent Developments
- Support from Innosuisse Swiss Accelerator:
- Date: June 19, 2023
- Detail: Received CHF 2.5 million to accelerate regenerative biomaterial development. The selection was made from 752 applications, positioning Volumina to upscale its production capabilities.
- Awards and Recognitions:
- Wins Top Innovation Award for Longevity Technology by Biopôle network (March 30, 2023).
- Recognized by EIT Health with a €0.5 million award.
- Funding Rounds:
- Successfully closed Series pre-A funding to further develop AdiPearl™ (October 3, 2022).
- Secured USD 21 Million for ongoing clinical program and research development (March 25, Updated on July 12, 2023).
- Partnerships:
- No specific partnership details are available other than the involvement in various interdisciplinary projects and industry recognition awards.
Conclusion
Volumina Medical SA is making significant progress in the field of regenerative medicine with its innovative approach towards developing biomaterials like AdiPearl™. Through strategic funding and support from industry accelerators, Volumina is positioned as a key player in the reconstructive and plastic surgery market, showcasing strong potential for future growth and market impact.
